Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer

Oncology Reports

Volumn 11, Issue 6, 2004, Pages 1225-1231

  Daga, Haruko ^a   Isobe, Takeshi ^a   Miyazaki, Mitsuru ^a   Fujitaka, Kazunori ^a   Kondo, Keiichi ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel; Platelet sparing effect; Thrombopoietin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; THROMBOPOIETIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KINETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; SQUAMOUS CELL CARCINOMA; THROMBOCYTE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SPECTROPHOTOMETRY, ATOMIC; THROMBOPOIETIN;

EID: 16544388472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.6.1225     Document Type: Article

References (34)

1. Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872, 1993. (Pubitemid 23304609)
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
3. Ramanathan RK and Belani CP: Chemotherapy for advanced non-small cell lung cancer: Past, present and future. Semin Oncol 24: 440-454, 1997. (Pubitemid 27355811)
4. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990. (Pubitemid 20239995)
5. Tamura T, Sasaki Y, Nishiwaki Y and Saijo N: Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86: 1203-1209, 1995.
6. Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606, 1995.
7. Canetta R, Bragman K, Smaldone L and Rozencweig M: Carboplatin: current status and future prospects. Cancer Treat Rev 15: 17-32, 1988.
8. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989. (Pubitemid 19272848)
9. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
10. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001. (Pubitemid 32591438)
11. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870, 1995.
12. Kearns CM and Egorin MJ: Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 24: 91-96, 1997.
13. Belani CP, Kearns CM, Zuhowski EG, et al: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676-684,1999. (Pubitemid 29075257)
14. Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 86:419-431, 1995.
15. Heits F, Katschinski DM, Wilmsen U, Wiedemann GJ and Jelkmann W: Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia. Eur J Heamatol 59: 53-58, 1997. (Pubitemid 27321175)
16. Sungaran R, Markovic B and Chong BH: Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 89: 101-107, 1997. (Pubitemid 26428183)
17. Guerriero A, Worford L, Holland HK, Guo GR, Sheehan K and Waller EK: Thrombopoietin is synthesized by bone marrow stromal cells. Blood 90: 3444-3455, 1997. (Pubitemid 27473414)
18. Fielder PJ, Gurney AL, Stefanich E, et al: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87: 2154-2161, 1996.
19. Emmons RVB, Reid DM, Cohen RL, et al: Human thrombopoietin levels are high when thrombocytopenia is due to mega-karyocyte deficiency and low when due to increased platelet destruction. Blood 87: 4068-4071, 1996. (Pubitemid 26152249)
20. Tahara T, Usuki K, Sato H, et al: A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 93: 783-788, 1996. (Pubitemid 26199318)
21. Miyazaki M, Fujiwara Y, Isobe T, Yamakido M, Kato T and Miyazaki H: The relationship between carbopratin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Res 19: 667-670, 1999. (Pubitemid 29168313)
22. Fujiwara Y, Takahashi T, Yamakido M, Ohune T, Tsuya T and Egorin MJ: Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 89: 260-262, 1997. (Pubitemid 27073765)
23. Ohe Y, Saijo N, Ohashi Y, et al: Preliminary results of the four-arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. Proc Am Soc Clin Oncol 22: 2509, 2003.
24. LeRoy AF, Wehling ML, Sposeller HL, Friauf WS, Solomon RE and Dedrich RL: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184-191, 1977. (Pubitemid 8213839)
25. Yamaoka K, Nakagawa T and Uno T: Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 223-252, 1987.
26. Van der Vijgh WJF: Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242-261, 1991.
27. Guminski AD, Harnett PR and deFazio A: Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48:229-234,2001. (Pubitemid 32758898)
28. Pertussini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ and Gewirtz AM: Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 97: 638-644, 2001. (Pubitemid 32113395)
29. Das KC and White CW: Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 272: 14914-14920, 1997. (Pubitemid 27251763)
30. Ghosh S, May MJ and Kopp EB: NF-κB and rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998. (Pubitemid 28183365)
31. De Botton S, Sabri S, Daugas E, et al: Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 100: 1310-1317, 2002. (Pubitemid 34864286)
32. Kaluzhny Y, Yu G, Sun S, et al: BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 100: 1670-1678, 2002. (Pubitemid 34925144)
33. Weigel TL, Lotze MT, Kim PK, Amoscato AA, Luketich JD and Odoux C: Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J Thorac Cardiovasc Surg 119: 795-803, 2000. (Pubitemid 30395478)
34. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.